Processa Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Processa Pharmaceuticals, Inc. on June 29, 2023, covering events that occurred on June 27, 2023. The filing primarily reports on the results of the Company's 2023 Annual Meeting of Shareholders and a subsequent amendment to its Certificate of Incorporation.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance actions and shareholder voting results.
Material Changes and Corporate Actions
- Authorized Share Increase: Effective June 27, 2023, the Company amended its Fourth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 50,000,000 to 100,000,000 shares.
- Board Election: Shareholders elected all six director nominees to serve until the next Annual Meeting. All nominees received significant "For" votes, with no "Against" votes recorded for any candidate.
- Accounting Firm Ratification: Shareholders ratified the appointment of BD & Company, Inc. as the independent registered public accounting firm for 2023.
- Executive Compensation: The advisory vote on executive compensation was approved by shareholders.
Shareholder Voting Results
| Proposal | For | Against | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| Election of Directors (All 6) | Varied (9.8M - 10.9M) | 0 | Varied (821K - 1.9M) | 2,477,214 |
| Amendment to Increase Authorized Shares | 12,430,395 | 1,736,546 | 40,799 | 0 |
| Ratification of Auditors | 12,862,749 | 398,544 | 946,447 | 0 |
| Advisory Vote on Executive Compensation | 9,724,358 | 1,916,645 | 89,523 | 2,477,214 |
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors related to the Company's operations. The document is a procedural report of shareholder meeting outcomes.
Key Facts for Investor Verification
- Verify the impact of doubling the authorized share count (from 50M to 100M) on potential future dilution.
- Confirm the composition of the newly elected Board of Directors and their tenure terms.
- Note the significant number of broker non-votes (2,477,214) on director elections and the executive compensation advisory vote, indicating shares held by brokers that were not voted on these specific matters.
- Review the attached Exhibit 3.1 for the full legal text of the Certificate of Amendment.